Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-10-04 pm EDT
42.66 USD   +1.74%
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/15Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08/03/2022 | 04:06pm EDT

NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 27,500 shares of common stock of the company and 14,500 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 1, 2022, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates. The stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting with respect to 1/48th of the shares underlying the options on each monthly anniversary thereafter, subject to the employee being continuously employed by the company as of such vesting dates. The stock options have a ten-year term and an exercise price of $50.63 per share, equal to the per share closing price of Ultragenyx’s common stock on August 1, 2022.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370


All news about ULTRAGENYX PHARMACEUTICAL INC.
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/15Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
09/12Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
AQ
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/07Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi's 17th Annual Bi..
CI
09/01Ultragenyx to Participate at Citi BioPharma Conference
GL
09/01Ultragenyx to Participate at Citi BioPharma Conference
AQ
08/23Goldman Sachs Adjusts Price Target on Ultragenyx Pharmaceutical to $74 From $72, Reiter..
MT
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 401 M - -
Net income 2022 -563 M - -
Net cash 2022 858 M - -
P/E ratio 2022 -5,65x
Yield 2022 -
Capitalization 2 988 M 2 988 M -
EV / Sales 2022 5,31x
EV / Sales 2023 5,63x
Nbr of Employees 1 119
Free-Float 95,1%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 42,66 $
Average target price 111,71 $
Spread / Average Target 162%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-49.27%2 988
REGENERON PHARMACEUTICALS, INC.17.10%78 592
VERTEX PHARMACEUTICALS36.90%76 279
BIONTECH SE-46.98%33 216
WUXI APPTEC CO., LTD.-39.54%29 067
GENMAB A/S-2.85%22 039